All In Biotech

Drug Trial Radar · NCT05548296

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

A Phase 2 Study of ACR-368 Therapy in Subjects With Endometrial Cancer

Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

350

Planned (sponsor's estimate)

Start

Aug 29, 2022

Primary completion

May 30, 2027

Study completion Nov 30, 2027

Sponsor

Lead sponsor
Acrivon TherapeuticsIndustry
Sponsor type
Industry
Collaborators
GOG Foundation
First posted
Sep 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.

Conditions

  • Endometrial Adenocarcinoma

Interventions

  • ACR-368Drug

    ACR-368 is an experimental drug

  • GemcitabineDrug

    Sensitization of tumor cells is provided through administration of ULDG

  • OncoSignatureDiagnostic test

    Prospective prediction of drug sensitivity based on a pretreatment tumor biopsy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Arm 1: Anti-tumor activity of ACR-368 in Endometrial cancer subjects that are OncoSignature Positive.Time frame: Response will be assessed every 8 weeks from baseline through 2 years or death.
  2. Arm 2: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects that are OncoSignature Negative.Time frame: Response will be assessed every 8 weeks from baseline through 2 years or death.
  3. Arm 3: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (Serous All-Comers).Time frame: Response will be assessed every 8 weeks from baseline through 2 years or death.
  4. Arm 4: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (Serous All-Comers).Time frame: Response will be assessed every 8 weeks from baseline through 2 years or death.

Locations

90 sites in 5 countries. Site status is shown where the registry gives one.

  • University of South Alabama Mitchell Cancer Institute

    Mobile, Alabama · Completed

  • Alaska Women's Cancer Center

    Anchorage, Alaska · Completed

  • HonorHealth

    Phoenix, Arizona · Recruiting

  • Arizona Oncology Associate, PC- HOPE

    Tucson, Arizona · Active not recruiting

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas · Recruiting

  • City of Hope National Medical Center

    Duarte, California · Recruiting

  • UC San Diego Moores Cancer Center

    La Jolla, California · Recruiting

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California · Completed

  • Cedars Sinai Medical Center

    Los Angeles, California · Recruiting

  • Hoag Cancer Center

    Newport Beach, California · Recruiting

  • UC Irvine Health

    Orange, California · Completed

  • Stanford Cancer Center

    Palo Alto, California · Recruiting

  • University of California, Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • University of California Los Angeles (UCLA)

    Santa Monica, California · Recruiting

  • University of Colorado

    Aurora, Colorado · Recruiting

  • Yale Cancer Center

    New Haven, Connecticut · Completed

  • Florida Gynecologic Oncology/Regional Cancer Center

    Fort Myers, Florida · Completed

  • Mount Sinai Comprehensive Cancer Center

    Miami Beach, Florida · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • Northeast Georgia Medical Center

    Gainesville, Georgia · Completed

  • Northwestern Medicine

    Chicago, Illinois · Recruiting

  • University of Illinois Cancer Center

    Chicago, Illinois · Recruiting

  • University of Chicago Medicine

    Chicago, Illinois · Recruiting

  • Carle Cancer Center

    Urbana, Illinois · Recruiting

  • Ascension St. Vicent Hospital, Inc.

    Indianapolis, Indiana · Recruiting

  • University of Iowa

    Iowa City, Iowa · Recruiting

  • LSU Health Sciences

    New Orleans, Louisiana · Recruiting

  • Trials365, LLC

    Shreveport, Louisiana · Recruiting

  • American Oncology Partners of Maryland PA

    Bethesda, Maryland · Completed

  • National Institutes of Health, Clinical Center

    Bethesda, Maryland · Active not recruiting

  • Holy Cross Hospital

    Silver Spring, Maryland · Completed

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • University of Massachusetts Chan Medical School

    Worcester, Massachusetts · Completed

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • HCA Midwest

    Kansas City, Missouri · Recruiting

  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

  • Rutgers Cancer Institute of NJ

    New Brunswick, New Jersey · Recruiting

  • Laura & Isaac Perlmutter Cancer Center

    New York, New York · Recruiting

  • New York Presbyterian Hospital-Columbia University Medical Center

    New York, New York · Completed

  • Memorial Sloan-Kettering Cancer Center

    New York, New York · Recruiting

Showing 40 of 90 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.